1. Home
  2. IIIN vs LYEL Comparison

IIIN vs LYEL Comparison

Compare IIIN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IIIN

Insteel Industries Inc.

HOLD

Current Price

$27.46

Market Cap

484.9M

Sector

Industrials

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$17.15

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIIN
LYEL
Founded
1953
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
484.9M
401.8M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
IIIN
LYEL
Price
$27.46
$17.15
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
156.7K
57.7K
Earning Date
04-16-2026
05-13-2026
Dividend Yield
4.37%
N/A
EPS Growth
112.12
N/A
EPS
0.65
N/A
Revenue
$647,706,000.00
$36,000.00
Revenue This Year
$14.20
N/A
Revenue Next Year
$6.82
$8,712.13
P/E Ratio
$42.42
N/A
Revenue Growth
22.39
N/A
52 Week Low
$24.35
$7.78
52 Week High
$41.64
$45.00

Technical Indicators

Market Signals
Indicator
IIIN
LYEL
Relative Strength Index (RSI) 50.23 38.32
Support Level $24.42 $15.74
Resistance Level $27.53 $19.02
Average True Range (ATR) 0.85 1.12
MACD 0.40 0.03
Stochastic Oscillator 82.10 41.50

Price Performance

Historical Comparison
IIIN
LYEL

About IIIN Insteel Industries Inc.

Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: